Patents Examined by D M Seaman
  • -[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
    Patent number: 9428460
    Abstract: The invention relates to N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides, intermediates and methods for their production, use thereof for treating and/or preventing diseases and use thereof for producing medicinal products and use thereof for treating and/or preventing diseases, especially of hyperproliferative diseases.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: August 30, 2016
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Duy Nguyen, Hermann Künzer, Hortensia Faus Gimenez, Benjamin Bader, Silke Köhr, Martin Fritsch
  • Benzopiperazine compositions as BET bromodomain inhibitors
    Patent number: 9422281
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) br’omodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: August 23, 2016
    Assignee: Forma Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
  • Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell
    Patent number: 9416101
    Abstract: Provided herein are novel compounds, pharmaceutical compositions for use, inter alia, in methods of reducing Wnt-mediated effects and treating cancer.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: August 16, 2016
    Assignee: STEMSYNERGY THERAPEUTICS, INC.
    Inventor: Darren Orton
  • Beta-lactamase inhibitors
    Patent number: 9403850
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: August 2, 2016
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Quinolone compound and pharmaceutical composition
    Patent number: 9403773
    Abstract: The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: August 2, 2016
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Otsubo, Yuji Ochi, Masami Nakai, Atsushi Mori
  • Process for preparing substituted indole derivatives
    Patent number: 9399621
    Abstract: The present invention relates to a process for preparing substituted indole derivatives. More particularly, the invention refers to a new method to synthesize indole-derivatives by oxidative C—H-functionalization.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: July 26, 2016
    Assignee: STUDIENGESELLSCHAFT KOHLE MBH
    Inventors: Martin Klussmann, Naeem Gulzar
  • Quinoline derivatives and their use in neurodegenerative diseases
    Patent number: 9399623
    Abstract: The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: July 26, 2016
    Assignee: Merck Patent GmbH
    Inventors: Srinivasa R. Karra, Yufang Xiao, Jeyaprakashnarayanan Seenisamy, Jayashankaran Jayadevan
  • Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors
    Patent number: 9394305
    Abstract: The present application relates to a series of substituted imidazo[1,2-a]pyridine compounds of formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: July 19, 2016
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Pradip Kumar Sasmal, Shahadat Ahmed, Ashok Tehim, Vidyadhar Paradkar
  • Pyridone amides as modulators of sodium channels
    Patent number: 9393235
    Abstract: The invention relates to pyridone amide compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: July 19, 2016
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Sara Sabina Hadida-Ruah, Corey Anderson, Vijayalaksmi Arumugam, Iuliana Luci Asgian, Brian Richard Bear, Andreas P. Termin, James Philip Johnson
  • Quinolone derivatives
    Patent number: 9394300
    Abstract: The present invention relates to novel compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: July 19, 2016
    Assignee: Cadila Healthcare Limited
    Inventors: Ranjit C. Desai, Vrajesh Pandya, Pankaj Ramanbhai Patel
  • Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
    Patent number: 9394256
    Abstract: The present invention features benzhydrol-pyrazole derivatives and related compounds having kinase inhibitory activity. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions, such as cancers, inflammatory disorders, or autoimmune disorders.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: July 19, 2016
    Assignee: X-Chem, Inc.
    Inventors: Anthony D. Keefe, Richard W. Wagner, Matthew Clark, Ying Zhang, Diana Gikunju, John Cuozzo, Heather Thomson
  • Process for the preparation of moxifloxacin hydrochloride
    Patent number: 9388178
    Abstract: The present invention relates to an improved and industriously advantageous process by means of providing coupling/condensing of wet mass of (1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid-O3,O4)bis(acyloxy-O)borate with (S,S)-2,8-diazabicyclo[4.3.0]nonane to give 1-cyclopropyl-7-[S,S]-2,8-diazabicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride (Moxifloxacin hydrochloride) of Formula-I with high purity.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: July 12, 2016
    Assignee: Mankind Research Centre
    Inventors: Harish Sharma, Bhuwan Bhaskar, Anil Kumar
  • Anti-angiogenic compounds
    Patent number: 9388138
    Abstract: (E)-2-(2-Quinolin-2-yl-propenyl)-phenol, 2-Quinolin-2-yl-ylethynyl-phenol and salts thereof are useful as medicaments, especially for treatment of an angiogenesis-related disease or disorder.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: July 12, 2016
    Assignees: UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMEBERS OF BOARD, OF THE COLLEGES OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
    Inventors: Breandan Douglas Kennedy, Alison Reynolds, Claire Kilty, Jacintha O'Sullivan, Andrew Douglas Baxter
  • Tetrahydroquinoline compositions as BET bromodomain inhibitors
    Patent number: 9388161
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: July 12, 2016
    Assignee: Forma Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot
  • Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
    Patent number: 9376393
    Abstract: A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon, uterus, nervous system, testis, adrenal gland, artery, vein, biliary tract, or eye.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: June 28, 2016
    Assignee: Clanotech AB
    Inventor: Yihai Cao
  • Bis-quaternary cinchona alkaloid salts as asymmetric phase transfer catalysts
    Patent number: 9376431
    Abstract: The invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. The present invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. On certain substrates and under specific reaction conditions, the inventors have discovered that the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis surprisingly provides for a more active and efficient process as compared to mono-quarternary catalysts.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 28, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Bangping Xiang, Nobuyoshi Yasuda
  • Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis
    Patent number: 9371286
    Abstract: The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: June 21, 2016
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Ho Jeong Kwon, Gyoon Hee Han, Hye Jin Jung, Jeong Jea Seo
  • Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
    Patent number: 9371318
    Abstract: Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: June 21, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio Rancati, Ian Linney
  • Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC
    Patent number: 9371295
    Abstract: The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like ?-thalassemia or sickle cell anemia.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: June 21, 2016
    Assignees: IRBM-SCIENCE PARK S.P.A., C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Sergio Altamura, Alberto Bresciani, Giulia Breveglieri, Danilo Fabbrini, Roberto Gambari, Steven Harper, Ralph Laufer, Edith Monteagudo, Emanuela Nizi, Paola Pace, Vincenzo Summa
  • Somatostatin receptor subtype 4 (SSTR4) agonists
    Patent number: 9371282
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: June 21, 2016
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf